Search PubMed⌕ Search

Biomedical subjects

J Cicciarelli

Publications and source records attributed to J Cicciarelli.

49 records · Page 3Linked to original sources
PubMed1987

Kidney transplantation and donor-recipient ages.

1. With CsA treatment there has been an increase in procurement of older kidneys and transplantation of older recipients. 2. Recipient age shows a 5% difference in graft survival between the best and the worst. In contrast, donor age shows a 16% difference in graft survival. 3. Female donor kidneys have a poor prognosis that is not completely associated with early function. This may indicate increasing dysfunction between one month and one year. 4. The drop in serum creatinine levels is directly proportional to recipient age. In zero- to 10-year-old recipients the rapid serum creatinine drop may be due to the transplantation of a normal size kidney into a small recipient. 5. Matching is strongly indicated for recipients receiving kidneys from young or old donors. 6. Transfusion is indicated for all groups and particularly for young donors and recipients. 7. Ten-year functional graft survival indicates decreasing immunocompetence with increasing recipient age. Ten-year graft survival with different aged donors indicates high risk with young and old donors.

Adolescent↗
PubMed1987

HLA-DR1 is a low responsiveness antigen in human kidney transplant recipients.

1. HLA-DR1 recipient phenotype showed increased overall and yearly graft survival. 2. Regraft and living-related HLA-DR1 recipients were found to have better graft survival. 3. Increased graft survival associated with the HLA-DR1 recipient phenotype was found in both CsA-and non-CsA-treated recipients. 4. Increased graft survival in HLA-DR1 recipient phenotypes was found within all matching groups. 5. HLA-DR1 phenotype was associated with low immunoresponsiveness. 6. HLA-DR1 donor kidneys when mismatched in the recipient were found to have lower graft survival.

Cyclosporins↗
PubMed1986

Cyclosporine and trends in kidney transplantation.

1. In the past 4 years there has been a definite trend to increase the number of first cadaver transplants using cyclosporine. In 1985, three fourths of the patients were treated with cyclosporine. 2. One-day, one-week, and one-month function data show that there is no increased nonfunction associated with the use of cyclosporine, and in those cases with a nonfunctioning kidney, one-year survival is higher with cyclosporine treatment compared with those patients who are not treated with cyclosporine. 3. Fewer patients treated with cyclosporine are transfused or A,B,DR matched compared with similar groups of noncyclosporine-treated patients. 4. Since the advent of cyclosporine, more kidneys have been used locally and, in addition, ischemia times are lower for cadaver kidneys. In addition, more diabetics are being transplanted with better results. 5. Cyclosporine does not seem to have an effect in living-related transplants that are one- or two-haplotype matched. There may possibly be deleterious effects associated with living-related transplants and the use of cyclosporine. 6. Patient survival since 1972 has increased one to two percentage points each year to the present time. This increase in patient survival is probably associated with those factors that strongly influence graft outcome (i.e., patient care, transfusions, matching, and immunosuppressive therapy).

Cyclosporins↗
PubMed1986

Regraft kidney transplant survival.

The salient features of one-year regraft transplant survival are as follows: 1. The effect of cyclosporine is less (about 7% increase in one-year graft survival) on regrafted patients than on first grafts. 2. In general we saw a HLA antigen matching effect in cyclosporine- and noncyclosporine-treated retransplant patients. 3. Patients who received living-related HLA two-haplotype matched kidneys did equally as well as a first or regraft recipient. 4. Transfusions seemed to have a minimal effect on regraft survival. 5. It is more important to match in patients who have PRA and the matching benefits translate into 61% and 75% one-year graft survival for zero DR and zero B,DR mismatched regraft patients, respectively. 6. In regrafts, female donor kidneys resulted in 15% lower one-year graft survival than male donor kidneys. 7. Retransplant patients from fair centers showed a significant 13% increase in one-year graft survival with cyclosporine. 8. Cold ischemia time, diabetes, and kidneys used locally or shipped had little effect on the regraft one-year survival. 9. The initial function of the retransplant kidney had a very large effect on the final one-year graft outcome of that kidney and was independent of the use of cyclosporine patients having a functioning kidney at one month had 75% and 72% one-year regraft survival with and without cyclosporine treatment, respectively. Patients having a nonfunctioning kidney at one month had 5% and 8% one-year regraft survival with and without cyclosporine treatment, respectively. 10. Responder and nonresponder classifications as defined by the duration of the first graft resulted in a 10 to 15% difference in regraft survival. 11. The effect of HLA-A,B matching was very strong in responder patients, i.e., there was a 32% difference in one-year regraft survival between zero mismatch and more than two antigens of mismatch. In nonresponder patients, the effect of HLA-A,B matching was only 5%. For HLA-DR locus matching, the difference was 12% for responders and 6% for nonresponders. 12. Cyclosporine use showed about a 10% increase in graft survival in responders and nonresponders. 13. Responder classification was also possible by separating patients who had initial function but no function at one month (responders) from those with function at one month (nonresponders).

Adult↗
PubMed1982

Monoclonal antibody against A1 Lewis d antigen produced by the hybridoma immunized with a pulmonary carcinoma.

A monoclonal antibody (CALed) against a human pulmonary squamous cell carcinoma line was cytotoxic to the line but did not react to an autologous B-lymphoblastoid line. Although the antibody was thought to be cancer specific, principally on the basis of this evidence, the antibody actually had the A1 Lewis d (Led) specificity. It reacted with approximately 2% of the random donor T-lymphocytes and with all six lymphocytes from donors who were A1 Led type without reacting to lymphocytes of any other type. The monoclonal antibody reactivity was also absorbed out by A1 Led red blood cells but not by red cells of other types. We conclude that the A1 Led antigen had been synthesized by the pulmonary carcinoma lines but not by the autologous lymphoblastoid line, resulting in disparity for this antigen. Since the combination A1 Led only occurs in 2% of the population, it is difficult to distinguish this type of antibody from tumor-specific antibodies.

Antibodies, Monoclonal↗
PubMed1981

Cytotoxic monoclonal antibody to a human leiomyosacoma.

A monoclonal antibody produced by the hybridoma technique against a human leiomyosarcoma was highly cytotoxic in dilutions of 1:64 000 to the original tumour cells. The antibody was unreactive with most normal cells (lymphocytes, 120 donors; spleen cells, 73/75; monocytes, 16; granulocytes, 25; platelets, 12; red cells, 11) and could not be absorbed out by smooth muscle from the small intestine or by spleen cells. Its specificity for the tumour was high since it did not react with cells from 40 patients with leukaemia, from 8 patients with other tumours, and from 7 cultured tumour lines. The only other cell that it reacted with (at 1:4000 dilution) was line 8402, a T acute lymphocytic leukaemia line. This monoclonal antibody may be suitable for therapeutic trials.

Antibodies, Neoplasm↗
PubMed1981

Functional properties of subsets of T lymphocytes defined by specific antigens.

Heteroantisera raised to the acute lymphocytic T (ALL) cell line HSB2 and to Sézary cells react with distinct subpopulations of T lymphocytes. Each antiserum reacts with a different T cell antigen and defines a distinct subpopulation that represents approximately 50% of peripheral blood T lymphocytes. The anti-HSB2-positive subpopulation contained suppressor cells for pokeweed mitogen-dependent immunoglobin (Ig) synthesis whereas the anti-Sézary cell serum-positive population included helper cells for Ig synthesis and mixed lymphocyte responder cells.

Antigens↗
PubMed1980

Discrimination of T, B, and null lymphocytes by electronic sizing.

T, B, and null lymphocytes isolated by sheep red blood cells (SRBC) rosetting or adherence to a nylon wool column had distinct size differences according to Coulter counter size analysis. The diameters in microns were as follows: B = 6.42, T = 6.76, null = 7.16, granulocytes = 8.42, and monocytes = 9.02. Coulter size distributions of cell preparations were compared to the proportions of cells with E, EAC, and surface immunoglobulin (SIg) markers in these preparations as well as their reactivity to HLA--DR antisera and rabbit anti-B-lymphocyte antisera. Cell preparations monitored by Coulter sizing produced the expected results in mixed lymphocyte culture (MLC) testing. That is, T cells responded but did not stimulate whereas B lymphocytes and monocytes stimulated but did not respond. NULL lymphocytes both stimulated and responded. In antibody-dependent cell-mediated cytotoxicity (ADCC), null lymphocytes and monocytes functioned as effectors, whereas T lymphocytes and granulocytes did not. B lymphocyte preparations were intermediate in activity. Coulter sizing is a rapid, simple means of assessing the purity of suspensions enriched for T, B, and null lymphocytes.

Animals↗
PubMedDate not supplied

The effect of individual HLA antigens on graft survival rates in kidney transplant patients.

We have used information available in the UCLA International Transplant Registry to study the effect of HLA antigens on graft survival outcome. All results showed that of all antigens tested, the presence of DRl in the recipient was associated with the highest graft survival rate. There was a positive matching effect for most DR antigens that were either presumed homozygous or heterozygous in the recipient. A regression analysis not only confirmed the association of DR1 and low immune response, but also suggested a greater importance of the DR rather than A or B locus to graft survival rates. Recipients with DR1.5 had the highest survival rates when DR1 was compared with other DR antigens and the heterozygous combinations of the two groups. This suggests that presence of heterozygous DR antigens may have combined effects on graft survival.

Follow-Up Studies↗